DarioHealth touts updated diabetes management software

DarioHealth updated logo

DarioHealth (NSDQ:DRIO) said yesterday it launched a new version of its Dario system and DarioEngage platform.

The new V4.2.0 update to both digital health programs are intended to improve user engagement, lower barriers to behavioral change and to streamline the experience and process efficiency for both users and their coaches, the Israel-based company said.

Read the whole story on our sister site, Drug Delivery Business News

Epitomee Medical raises $8m for novel weight-loss device

Epitomee Medical

Early-stage medical device developer Epitomee Medical said today that it raised $8 million in a new round of equity financing to support its novel Epitomee Capsule “shapeshifting” pill intended to prevent diabetes and promote weight loss.

The Israel-based company said that its Epitomee Capsule contains a shape-shifting scaffold that, after it is ingested, helps the body have an early sensation of fullness and prolonged gastric emptying through direct mechanosensory stimulation.

The pills are designed to be taken twice a day to lower caloric intake and promote weight loss, Epitomee Medical said.

“The Epitomee solution is  a novel practical approach in the fight against the global obesity epidemic. The combination of a simple, self-administered capsule and a high degree of safety and effectiveness makes it an optimal solution to this epidemic. The new partnership and this financing provide Epitomee with the resources to complete its next phase clinical trial  and reach a significant  value inflection point,” co-founder & chair Dr. Shimon Eckhouse said in a prepared statement.

Data from an initial clinical study of the capsule indicated that the device met its endpoints and showed weight loss and glycemic control improvement, as well as ameliorated blood pressure levels and no safety concerns within 12 weeks of treatment.

“The Epitomee Capsule has the potential to be the first-line, drug-free treatment for overweight, prediabetic, and moderately obese people. We are excited that it is well received, and that patients and physicians see excellent and consistent  results in our clinical work. With the current financing, we can advance the clinical program and bring the company’s solutions closer to the millions of patients in need,” CEO Dr. Dan Hashimshony said in a press release.

Medtronic, BCBS Minnesota ink value-based diabetes deal

Medtronic logo updatedMedtronic (NYSE:MDT) said today that it inked a deal with Blue Cross & Blue Shield of Minnesota on an outcomes-based program for diabetes patients.

The plan gives BCBS Minnesota members access to Medtronic’s Guardian Connect continuous glucose monitor via a pharmacy benefit, with payments pegged to how long patients spend in a targeted blood glucose range. The deal also includes access to the company’s Inner Circle patient engagement program, which aims to use gamification to improve outcomes, for people using Guardian Connect and Medtronic’s MiniMed 670G pump.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic, BCBS Minnesota ink value-based diabetes deal appeared first on MassDevice.

Cigna lowers insulin price to $25 per month

Under pressure from patients and the FDA, Cigna (NYSE:CI) and Express Scripts said today that they will lower the price of insulin to $25 per month for some patients.

Three firms — Eli Lilly, Novo Nordisk and Sanofi — control 90% of the global insulin market and produce all the insulin used in the U.S. Insulin list prices regularly increase by double digits annually, according to the FDA, which attributed the price hikes to a lack of competition.

Get the full story on our sister site, Drug Delivery Business.

Biolinq adds $5m to Series A

BioLinq

Biosensor developer Biolinq said today it raised $4.8 million as an extension of its Series A financing round.

The San Diego-based company said that the investment in its expanded, oversubscribed Series A round was led by the JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners. With the additional funding, Biolinq said it has raised a total of $15 million in the Series A round.

Read the whole story on our sister site, Drug Delivery Business News

The post Biolinq adds $5m to Series A appeared first on MassDevice.

Valeritas inks Israeli distro deal with Tritech Biomed

Valeritas logo - updated

Valeritas (NSDQ:VLRX) said today that it inked an exclusive distribution deal with Tritech Biomed to commercialize its V-Go wearable insulin delivery device designed for patients with Type 2 diabetes in Israel.

Through the deal, the Bridgewater, N.J.-based company said that Tritech Biomed will have rights to promote, market and sell the V-Go system to diabetes clinics and patients in the region.

Read the whole story on our sister site, Drug Delivery Business News

The post Valeritas inks Israeli distro deal with Tritech Biomed appeared first on MassDevice.

DarioHealth, Glytec ink joint marketing deal

DarioHealth, Glytec

DarioHealth (NSDQ:DRIO) said today it inked a joint marketing agreement with Glytec through which DarioHealth’s smart glucose meter will be able to transmit information to Glytec’s Glucommander Outpatient software.

Israel-based DarioHealth said that blood glucose data from its Dario Blood Glucose Monitoring System will now be imported into the Glucommander Outpatient for use in conjunction with other clinical data to create personalized insulin dose recommendations.

Read the whole story on our sister site, Drug Delivery Business News

The post DarioHealth, Glytec ink joint marketing deal appeared first on MassDevice.

Medtronic responds to usability concerns for its MiniMed 670G insulin pump

Medtronic logo updatedMedtronic (NYSE:MDT) responded to a study presented this week which highlighted usability concerns with its MiniMed 670G automated insulin pump, writing that the company had “made many enhancements to the system since the study was done which would likely mitigate many of the issues experienced.”

Earlier this week, physicians from Boston Children’s Hospital reported that nearly one-fifth of participants in a real-world study of the MiniMed 670G stopped using the system within months of it being prescribed, citing dissatisfaction with the technical demands of the system.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic responds to usability concerns for its MiniMed 670G insulin pump appeared first on MassDevice.

Study examines usability of hybrid closed-loop insulin pump

Boston Children's Hospital - updated logoData from an 83-person study of Medtronic‘s (NYSE:MDT) MiniMed 670G hybrid closed-loop insulin pump showed that nearly one-fifth of participants stopped using the device after struggling with the technical demands of the system, researchers reported.

Medtronic’s MiniMed 670G device is designed to automatically track and adjust a patient’s blood sugar levels by measuring blood glucose every five minutes and automating the administration of insulin.

Get the full story at our sister site, Drug Delivery Business News.

The post Study examines usability of hybrid closed-loop insulin pump appeared first on MassDevice.

Senseonics touts patient access program for Eversense CGM

SenseonicsSenseonics (NYSE:SENS) said today that it launched the Eversense Bridge Program, which is designed to improve patient access to Senseonics’ Eversense continuous glucose monitoring system.

The company said that the program can help users confirm their insurance benefits and obtain pre-authorization before sensor placement. The Eversense Bridge Program is also meant to help healthcare providers and patients appeal to insurers regarding denied claims.

Get the full story at our sister site, Drug Delivery Business News.

The post Senseonics touts patient access program for Eversense CGM appeared first on MassDevice.